Anteris Technologies Global Corp. (ASX:AVR)

Market Cap	278.08M
Revenue (ttm)	3.23M
Net Income (ttm)	-127.48M
Shares Out	41.20M
EPS (ttm)	-3.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,166
Average Volume	17,187
Open	6.33
Previous Close	6.33
Day's Range	6.20 - 6.75
52-Week Range	4.26 - 13.36
Beta	0.41
RSI	51.20
Earnings Date	Nov 20, 2025

About ASX:AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 136
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVR

Financial Performance

In 2024, ASX:AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.

Financial numbers in USD